GB3226
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for GB3226, covering 2025-07-24 to 2025-07-24. Get the full timeline:
Most recent: Clinical Trial Update: An Open-label, Dose-Escalation and Dose-Expansion Study of GB3226 in Patients With Relapsed/Refractory Acute Myeloid Leukemia [Phase 1, Phase 2]